Vaxcyte (NASDAQ:PCVX) COO Jim Wassil Sells 2,250 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the transaction, the chief operating officer directly owned 158,494 shares in the company, valued at approximately $7,848,622.88. This represents a 1.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.83, for a total value of $127,867.50.
• On Tuesday, March 10th, Jim Wassil sold 7,395 shares of Vaxcyte stock. The stock was sold at an average price of $58.88, for a total value of $435,417.60.

Vaxcyte Stock Down 1.0%

PCVX stock opened at $46.93 on Thursday. The company has a market cap of $6.78 billion, a P/E ratio of -6.82 and a beta of 1.24. Vaxcyte, Inc. has a twelve month low of $29.08 and a twelve month high of $65.00. The business has a fifty day moving average of $55.49 and a 200-day moving average of $52.76.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the prior year, the company posted ($1.04) earnings per share. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -7.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PCVX. Royal Bank of Canada increased its holdings in Vaxcyte by 115.2% in the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock valued at $1,113,000 after purchasing an additional 15,774 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Vaxcyte in the first quarter valued at about $219,000. Caxton Associates LLP acquired a new position in Vaxcyte in the first quarter valued at about $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Vaxcyte by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock valued at $19,409,000 after acquiring an additional 41,034 shares during the period. Finally, Cetera Investment Advisers grew its stake in Vaxcyte by 13.8% in the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after acquiring an additional 932 shares during the period. Institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. BTIG Research upped their price objective on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Jefferies Financial Group reiterated a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.